Volume 30, Number 10—October 2024
Dispatch
Mpox Epidemiology and Vaccine Effectiveness, England, 2023
Table 3
Vaccination status of mpox case-patients used to estimate vaccine effectiveness of various doses of Modified Vaccinia Ankara–Bavarian Nordic vaccine by using the screening method, England, 2023*
Doses | Cases in 2023 | Corrected cases† | PCV, % |
PPV, % | PPV, sensitivity, %‡ | VE, % (95% CI) | VE sensitivity, % (95% CI)‡ | |
---|---|---|---|---|---|---|---|---|
0 | 54 | 65.4 | 52 | 16 | 30 | |||
1 | 20 | 24.2 | 19 | 38 | 32 | 84 (74–91) | 65 (42–79) | |
2 | 30 | 36.4 | 29 | 45 | 38 | 80 (69–83) | 56 (31–72) | |
Unknown | 22 | |||||||
1 or 2 | 50 | 60.6 | 48 | 84 | 70 | 82 (74–88) | 60 (41–73) | |
Total | 126 | 126 |
*PCV, percentage of case-patients with the given number of doses; PPV, percentage of the population with the given number of doses obtained by matching each case to the population uptake 14 d before onset and averaging this across cases; VE, vaccine effectiveness. †22 case-patients with unknown vaccination status distributed among 0, 1, and 2 doses. ‡Based on the higher estimated denominator for gay, bisexual, men who have sex with men (107,088).